UIUNTI BIOSGIEIIGES lIilIIIHI

(Forme y known as lvee Inledaa Limited)

380 006'
office:702, 'A Wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad
Regd.
Phone:079 - 65410862 emaili info@iveeinieciaa com CIN: t24U0G11982P1C005057

Feb(uatY 74, 2077

To,
Department of CorPorate Services
Bombay Stock Exchange Limited
25'n Floor, P. J. Tower,
DalalStreet,
Fort, Mumbai-400 001.

Dear Sir/Madam,
Sub: Outcome of Board Meeting

ThisistoinformyouthattheBoardofDirectorsofthecompanyinitsmeetingheldtoday
Registered office
i.e, on Tuesday, February 14, 2017 from 11.00 A.M to 12 45 P M', at the
li atr" cotp.nv, inter aiia has considered and approved the standalone and consolidated
UnauditedFinancialResu|tsforthequarterendedDecember3l,2016a|ongwith-Limited
Review Report thereon.

Please take the above on your records.

Thanking You,

Yours faithfully,

For Vivanza Biosciences Limited

.-l-l q"r lnt. lt'lLc

Harshul K. Shah
Diredor
DIN: 01955747
 (Formerly Known a3IVEE lt{JEcTM LTD )
Reoiltcd Oiie 702'A wnq, Ashola ChaFbe6, Rasla Marg Ehisbndge Aimedabad 340 006
clN : 1241 1oCJ1932PLC005057
STATEI\IENT OF STAI{OAIONE UNAIJDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31

hc@se/D@ease in inventoies of FG. WIP 6nd slock-intad

/ (Lc.) rrcm op.Ftion. dob other Incore, tln.n@

Profh/ (Lo$) trom ordin.ry .ciivili.. beloB fln.ne ccrs

Proft / {L@) ton odir.ry actlvltles afte. f Mn@ cGt bur

Ner Protlt / {L@) tor th p.riod (ll-12)

Pbfil / ( Lo$) or ossiat6 '

Net Prctn / { L@ ) .ri.r tar* , mlnorlty Inleest and 3hae

proft / ( r@ ) of ..tociat6 ( 13 r 'la r 15 )r

EamlnF Per Sh.@ (btor .rtr.ordlnary lGme) {not

ings P.r Shab (.fter enr.ordin.ry iltu) (nol

1. The above siandalone unEuditd financial resulls {e viewed by|ns slatulory Alditors , commmended by lhe
ComFitles and taken on re6rd by the Board of Oirsctols at their tneeting held on Tuesday 14 February,2017
2. Comoanv ooerates onlv n sinqle seomenl i..oharmacaulbab lelated aclivities
3. The Statfuoi Audno6 havs ca.ried ad a limiad vi4 of the financiat reslllts lor th quader snding Docmbs 31 , 2016.
4. The previous quadef$tea/s Rgulos have ben grcupednearanged wheEver necessary to mak it comparable
wlth the cufienl quanerryear

For, VIVANZA BIOSCIENCES LIMITED

crhvt.,{.rtq\
Oale | 140212017
Kf\ai!
Ahmedt';ai

{4
 GMCA&Co.
Chafiered AccoLtnlants
Oltice Nt LG Showroom' Milhakhali six Road' Navrangpura,
101, "Parishram". 5-8. Rashmi SocietY.
Ahmedabad-380 009. Ph : 079-40037372 E-mall : gmca19?3@ gmail com

Audito/s Report on standalone Quarte y Financial Results an,c year

to Date Restllts ofvivanza
Biosciences Ltd. pursuant to Regulati;n 33 ofthe SEBI
{Listirg oUtijution-, Otr"foru""
Requirements)Regulations,2015 "nO

IndependentAtditots, Review ReDort

To
The Boa.d ofDirectors,
Vivanza Biosciences Ltd.

y: hl* *u]:y"_d rhe accompanyrng statement ofStandalone Unaudited Financial results

ofViyanza
broscrences Ltd. ior the quarter ended 31st December, 2016,
attach,ed herewith,being submjtted by
me compary pursuant to the requirem,ent of Regulatlon 33 of the SEBI (Listing
obligations anl
Disclosure RequirementsJ Regulatior! 2015. ?his statement which is
the resp,=onsibility of ttre
Company's Management and approved by the Board of Directors, has been prepared
in aciordance
wjth the recognition & measurement principles laid down in the /lccounting
Standard for Interim
irinancial Reporting (AS ZSJ, prescribed under section 133 of the Companies
Act, 2013 and other
accounling principles generally accepted in India. our responsibility
is to ,..ue a report on ure
statement based on our review.

we conducted our review ofthe statement ir accordance with the standard on Review
nReview Engagements
[sRE] 2410 of Interim Financiar information performed by the tndependent Auditor of the
nntity" issued by the Institute of Chartered Accountants oflndia. This standard
requires that we plan
& perform the review to obtain moderate assurance as to whether the statement is hee of Matirial
Misstatement, A.review.is limited prima.ily to Inquires of the Company's personnel
& analytical
procedures applied to the financial data & thus provide less assurince
than audit. we have not
performed an Audit & accordinglywe do not express an Audit opiniorL

Based on our review conducted as above, nothing has come to our attentjon
that causes us to believe
that the accompanying statement of unaudited fiaancial results prepared in accordance with
accounting standards and oEher recognized accounting practices and_poiicies has rot discrosed
the
inlormation requjred ro be disclosed in terms of Regulation 33 ofthe SEBI (Listing
Obligations &
Disclosure Requirements) Regulatiols, 2015 includihg the manner jn which it is to
be disclosed, or
that ilcontains any material misstatemenl

FoT,GMCA&CO.

4e1-{..}\ Chartered Accountants

FRN:109850W

Place: Ahmedabad
akdt /L'\ \' fll
/
., ( ( 41'
'\

CA.
)

Miit
!

--/
--''

S. Paral
)

Dater 14th February 2017 t/ Partner

lvlembersh:p No: 163940
 BtosclENcEs LlMlrEo
(Formsrly Known a! IVEE INJECTAA LTD )
RorsFFd Olllce. 702 'A- {no chanbeB R6sla MaE E lisbridg ahmedsbtd 330 006
- Ashofia
CIN : L2411OGJ 1932P1C00505?
.OF qUAR'ER ENDED DECEMBER 3t 2OI5'
CONSOLIDAIE UNAUOITED FIMNCIAL RESULTg FOR '
'HE
r.. In1.6 ercpt per sha!!4!l
-vtvANzA 31liz2oi6 | 30,!s/2016 31tl2t2016

1 Tahcome fren o!.Etlo@

:r h6me lrcm ooelioB 4a.161 46.
0.00
b) olner opsting h@6
2
122.64
lbl Purchde oI sicck-in-lrade
h tn.Esrnffis. rNenron* oi FG wlP and e10c*jn-lr.d0
'n 15.03
0.o
10.61 17.U
'n O$q sDruas
64,
erettt I aet trc. opmttoB b.iore oth.r In@ns, f,n'ne eb
3
'nd -m.0s

F;iiliiiiifin ono:tnary actlvlrd b.rorc tlnan@ cGt! ad rc.ptron.l

-19.90 a9.63 4331
0.03 0.01

Frottt t {ross) lrom odtnary acttvttlB afiar llnanc. cd!8 btli belore
-19.91 -t.6,r 4it,95
1
0.00 0.0r
3
-9,6{ .ait,95
Pbfit / llo.sl lbm odinarv .ct|vru.. b.ioE ttr l7{l
0.00 0.00 0.0(
L9 -19.93 4!,95
Net f,rotlt / iLAsl ftom ordinrfl ,fter tlx tg_i 0l
0.0c
12
NetPrcrt, {Lo.a) ror the pedod {l I r 2) t93: .13.96

shre or Prorl / ( Loss) or asgiEts' 0.0( 0.0( 0,0{

0.00
15
16 Net ) af!.r t r8 J"lio'ltv ri ee.t .nd .h.G ol
Prefltl b-.; prollt , ( lor.
ol ..slat6 l3 + i4 + 15 )'
I -19.93 4:t,95
17 rMih/ sh. eoibl Gac value ol lO/-6adl 255.0C 255.0C 255.00
newe. exduoins Revalualion n3.fls as per balence shet ol pBious
13
'.6-nlinovea.
Eiiiiig Por shds to.roe extrdodlnary it6rnll (not .nnudl.od):
19.1
-o. -0.38
-0.73
oruted
Ednms. F; Sh.'iatter extaodharv hen.) (not .nnu.ll..d):
19.ii
-0.7t -1.72

i'liii atove consorioare unaudited fnanoal Boad

sufts w v,swd by rh st.tutory Auditors fecommmended by rhe ,

;r;iii;;;k;;;al"L"ii ;" recod bv the ie phEmceuticab

of Direclon at thelr melins held on ruesdav 14 Febru6ry ' 2017
relaled actvilies
2. Company operalos onty in single segment -our
a. irii6lti,r"iv A"o,t"" i,a"" c;nied
-Liii"ii"n""" timited Eview of the financiat rcsuls for rhe quaner endins DecEmter 31 , 2016.
i. vu"".. p,i*r" Ltmlred (iom6dy Fodune Bevuss privare LiFitd) (vLpL) b6.ame whorry oMrr subsidiary
; rire ComDanv w e.r. tune r r, 20 18. H;ncs. figurcs for corespond'ng
qErrr nded and yr to dale figures ior $e p@lous
ta snd fsus for lhe prevols vear 6nded a nol avallable and provided ior'

%d
 GMCA&Co.
Chartered Accountants
Olilce 101. 'Pa.i5hram", 5-8, Rashmisocioly, Nr. LG Showroom, Mithakhali Six Road' Navfangpura
Ahmedabad-38o 009. Ph. : 079-40037372. 'mai!: gmca19;r3@gmail.com

rdependentAudltors, Beview Repoft

1o
The Board ofDirectors,
Vivanza 3:osciences Limited

Wehave reviewed the accompanying statement sfConsolidated Unaudited Financial

results
oJ Vivanza Biosciences Limited (The Hoiding Company) and its Subsidiary
Company Cfhe
Holding Company.and its Subsidiary Collectively referred to as "the croup;) for tie quirter
ended 3lstDecember, 2016, attached herewith, beihg submitted by the Holding company
pursuant to the requirement ofRegulation 33 ofthe SEBI (Listing obiigations
and Disclosure
Requirements] Regllation, 2015. This statement which is tho r-sponiibility of the olding
Company's Management and approyed by the Board of Djrectors, has been prepared
in
accordance with the recggnition & measurement prjnciples laid down in the
Aciounting
Standard for Interim Financial Reporting (AS 25), preicrltred under section
133 of the
Companies Act 2013 read witi relevant rules issued there under or by the Inititute
of the
Charlered Accountants of Indj4 as applicable and other accounting principles genenlly
accepted in India. our responsibility is to issue a report on the statement based on
ou.
revtew.

We conducted our review of the statement in accordance with the Standard on Review
Engagements [SRE) 2410 "Review of Interim Financial Intermarion peformed bv the
lndeperdent Auditor ofthe Entiy'issued by the Institute ofchartered Accountants ofi',dia.
This slardard requires that we plan & perform the review to obtain moderale assurance as
to whether the statement is free of Matetial Misstatemenl A rcv:ew is limited Damarilv to
Inquires of the lolding Company's personrel & analytical procedures apptied to "the
fioancial data & thus ptovide less assurance than audit. We hirve not performed an Audit &
accordingly we do nor express an Audit opinion.

The statement includes the results of the wholy-owned subriidiary vivanza Life sciencies
Private Limited (The Subsidiary Company)

We did not review the lnte m Financial Results ofthe Subsidiarywhose Interim Financial
Information reflects NIL Revenue & Rs. g,OZ,5Z3/" Net Loss after tax for the Ouarter ended
31rt December, 2016. This inlerim financial information of the subsidiary h;ve not been
audited by the any Auditors rather they have been signed & declared by th; Directors ofthe
Company& our report on the statement, in so faras it relates to the amounts and disclosures
included irl respect of the Subsidiary is based sole]y on the Financial Statements sisned &
declared by the Board ofDirectors ofthe Subsidiary Company.

Based on our review conducted as above, and based on consideration of the sisned &
declared Financial Statements referred in the above paragraph, nothing has.orJto or.
attention thatcauses us tg believe that the accompanying statement p.epared in accordance
with accounting standards specified under section 133 of the Companies Act, 2013 read
wlth rule 7 of the Companies (Accounrs) Rules, 2014and rther iecognlzed accuunting
practices and policies has not disclosed tlle information requlrd to be disclosed in trsrs of
Regulahon 33 of the s.EBl (Lisdng Obligrtions & Disclosure Requiremntq) Regulatiots,
2015 includiDg the ftanner in wbicb tt ts to be discloEed, or that lt contalDf anv mafTial